MCID: ALC006
MIFTS: 61

Alcoholic Hepatitis

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Alcoholic Hepatitis

MalaCards integrated aliases for Alcoholic Hepatitis:

Name: Alcoholic Hepatitis 12 74 15 32
Acute Alcoholic Liver Disease 12 71
Acute Alcoholic Hepatitis 12 54
Hepatitis, Alcoholic 17 71
Hepatitis Alcoholic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12351
ICD9CM 34 571.1
NCIt 49 C34352
SNOMED-CT 67 9953008
ICD10 32 K70.1
UMLS 71 C0001306 C0019187

Summaries for Alcoholic Hepatitis

MalaCards based summary : Alcoholic Hepatitis, also known as acute alcoholic liver disease, is related to hepatitis and hepatic coma. An important gene associated with Alcoholic Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetylcysteine and Caspofungin have been mentioned in the context of this disorder. Affiliated tissues include liver, neutrophil and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 74 Alcoholic hepatitis is hepatitis (inflammation of the liver) due to excessive intake of alcohol.... more...

Related Diseases for Alcoholic Hepatitis

Diseases related to Alcoholic Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 882)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.8 TNF SLC17A5 KRT18 GPT GGT1 F2
2 hepatic coma 31.6 GPT F2 ALB
3 hepatorenal syndrome 31.5 GPT F2 ALB
4 fatty liver disease, nonalcoholic 1 31.3 SLC17A5 PNPLA3 GPT GGT1
5 hepatic encephalopathy 31.2 TNF SLC17A5 IL6 GPT F2 ALB
6 alcohol use disorder 31.2 SLC17A5 GPT GGT1 CYP2E1 ALB
7 fatty liver disease 30.9 TNF TLR4 SLC17A5 PNPLA3 KRT18 IL6
8 alcohol dependence 30.8 TNF SLC17A5 IL1B GPT GGT1 CYP2E1
9 acute liver failure 30.7 SLC17A5 HGF GPT F2 ALB
10 active peptic ulcer disease 30.6 F2 CRP ALB
11 cholestasis 30.6 TNF SLC17A5 IL6 GPT GGT1 F2
12 esophageal varix 30.5 GPT GGT1 F2 ALB
13 kwashiorkor 30.5 SLC17A5 GPT F2 CRP ALB
14 antipyrine metabolism 30.5 F2 ALB
15 acute kidney failure 30.5 HGF GPT F2 ALB ADAMTS13
16 pneumocystosis 30.5 TNF IL6 CRP ALB
17 hepatitis c 30.4 TNF KRT18 IL10 GPT GGT1
18 fournier gangrene 30.4 F2 ALB
19 portal hypertension 30.4 TNF TLR4 PNPLA3 GPT F2 CXCL8
20 bilirubin metabolic disorder 30.4 SLC17A5 GPT GGT1 F2 CRP ALB
21 eclampsia 30.3 TNF IL6 F2 ALB
22 liver cirrhosis 30.3 SLC17A5 LBP KRT18 HGF GPT GGT1
23 deficiency anemia 30.3 TNF IL6 GGT1 CRP ALB
24 infantile liver failure syndrome 1 30.2 SLC17A5 GPT F2 ALB
25 hepatitis a 30.2 TNF TLR4 IL1B IL10 GPT GGT1
26 splenic infarction 30.2 GPT F2 CRP ALB
27 paralytic ileus 30.2 GPT F2 CRP ALB
28 hepatitis e 30.2 TNF GPT GGT1 F2 ALB
29 nutritional deficiency disease 30.2 IL6 F2 CRP ALB
30 invasive aspergillosis 30.2 TLR4 IL10 CXCL8
31 varicose veins 30.1 TNF IL6 ICAM1 F2 CXCL8 CCL2
32 metabolic acidosis 30.1 IL6 GPT F2 ALB
33 tuberculous peritonitis 30.1 CRP ALB
34 alpha-1-antitrypsin deficiency 30.1 TNF GPT F2 CXCL8 ALB
35 infective endocarditis 30.1 TNF LBP IL6 F2 CRP
36 drug-induced hepatitis 30.1 TNF GPT F2 CYP2E1 ALB
37 cholelithiasis 30.0 GPT GGT1 CRP ALB
38 allergic hypersensitivity disease 30.0 TNF IL10 ICAM1 CXCL8
39 disseminated intravascular coagulation 30.0 TNF IL6 IL10 GPT F2 CRP
40 legionnaire disease 30.0 TLR4 KRT18 CRP
41 cholecystitis 30.0 TLR4 KRT18 GPT F2 ALB
42 mumps 30.0 TNF IL6 IL1B IL10 CXCL8
43 cytomegalovirus infection 30.0 TNF IL6 IL1B CXCL8 CCL2
44 protein-energy malnutrition 29.9 TNF IL6 GPT GGT1 ALB
45 hypothyroidism 29.9 TNF GPT F2 CRP ALB
46 acute kidney tubular necrosis 29.9 TNF IL6 HGF GGT1 ALB
47 adult-onset still's disease 29.9 TNF IL6 IL1B CXCL8 CRP
48 gastric ulcer 29.8 TNF IL6 IL1B HGF CXCL8
49 thrombocytosis 29.8 IL6 IL1B F2 CRP ALB
50 purpura 29.8 TNF IL6 IL10 F2 CRP ADAMTS13

Comorbidity relations with Alcoholic Hepatitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcoholic Gastritis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Deficiency Anemia Fatty Liver Disease
Hepatic Encephalopathy Portal Hypertension
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Alcoholic Hepatitis:



Diseases related to Alcoholic Hepatitis

Symptoms & Phenotypes for Alcoholic Hepatitis

MGI Mouse Phenotypes related to Alcoholic Hepatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ADAMTS13 ALB CRP CYP2E1 F2 GGT1
2 cardiovascular system MP:0005385 10.14 ALB CRP CYP2E1 F2 HGF ICAM1
3 hematopoietic system MP:0005397 10.11 ADAMTS13 F2 GGT1 HGF ICAM1 IL10
4 immune system MP:0005387 10.07 ADAMTS13 ALB CCL2 CRP F2 GGT1
5 liver/biliary system MP:0005370 9.85 ALB CYP2E1 HGF IL10 IL6 KRT18
6 mortality/aging MP:0010768 9.8 ADAMTS13 ALB CYP2E1 F2 GGT1 HGF
7 neoplasm MP:0002006 9.23 ALB CYP2E1 ICAM1 IL10 IL1B IL6

Drugs & Therapeutics for Alcoholic Hepatitis

Drugs for Alcoholic Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Lenograstim Approved, Investigational Phase 4 135968-09-1
6
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
9
Choline Approved, Nutraceutical Phase 4 62-49-7 305
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
14 Respiratory System Agents Phase 4
15 Antidotes Phase 4
16 Expectorants Phase 4
17 N-monoacetylcystine Phase 4
18 Lecithin Phase 4
19 Polyene phosphatidylcholine Phase 4
20 Trace Elements Phase 4
21 Nutrients Phase 4
22 Micronutrients Phase 4
23 Anti-Infective Agents Phase 4
24 Vitamin B 6 Phase 4
25 Vitamins Phase 4
26 Vitamin B Complex Phase 4
27 Folate Phase 4
28 Vitamin B9 Phase 4
29 Antifungal Agents Phase 4
30 Anti-Infective Agents, Local Phase 4
31 Metadoxine Phase 4
32
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
33
Propranolol Approved, Investigational Phase 3 525-66-6 4946
34
Norfloxacin Approved Phase 3 70458-96-7 4539
35 Ethiodized oil Approved, Investigational Phase 3 8008-53-5
36
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
37
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 6436173 46783403
38
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
39
Lactulose Approved Phase 2, Phase 3 4618-18-2 11333
40
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
41
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
42
Atorvastatin Approved Phase 3 134523-00-5 60823
43
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
44 Molgramostim Investigational Phase 3 99283-10-0
45 Vasodilator Agents Phase 3
46 Cytochrome P-450 Enzyme Inhibitors Phase 3
47 Anti-Arrhythmia Agents Phase 3
48 Pharmaceutical Solutions Phase 3
49 Hormones Phase 2, Phase 3
50 Hormone Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
2 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
3 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
4 Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis Completed NCT02161653 Phase 4 Prednisone plus Metadoxine;Pentoxifylline plus Metadoxine
5 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
6 Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients Completed NCT01413360 Phase 4 High dose vitamin C
7 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
8 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Completed NCT01501162 Phase 4 hepatitis, alcohol, probiotics;alcohol, hepatitis, Placebo
9 Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis Recruiting NCT03703674 Phase 4 GCSF
10 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
11 Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis Unknown status NCT02485106 Phase 3 Rifaximin;Corticosteroid or pentoxifylline
12 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
14 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
15 N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial Completed NCT00962442 Phase 3 N-Acetylcysteine;placebo
16 Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study. Completed NCT00863785 Phase 3 Corticoids plus N Acetyl Cysteine
17 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Completed NCT01471028 Phase 3
18 Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
19 Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects With Acute On Chronic Hepatitis (AOCH) Completed NCT00973817 Phase 2, Phase 3
20 A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
21 Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) Completed NCT01143246 Phase 3 Terlipressin;Placebo
22 Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF) Completed NCT01383460 Phase 3 Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO);Placebo
23 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
24 The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis Recruiting NCT03069300 Phase 3 N-acetyl cysteine (NAC)
25 Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study Recruiting NCT02442180 Phase 3 G-CSF (Filgrastim injection);steroid;placebo
26 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
27 Granulocyte Colony Stimulating Factor Therapy In Decompensated Cirrhosis Of Liver: A Double Blinded Single Centre Randomised Controlled Trial Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
28 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Active, not recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
29 Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina Active, not recruiting NCT03696940 Phase 3 L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg;Atorvastatin 10mg
30 Therapeutic Plasma Exchange in Patients With Acute on Chronic Liver Failure: A Randomized Controlled Trial (PLEXAR) Not yet recruiting NCT04051437 Phase 3 Standard medical treatment
31 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
32 A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Terminated NCT02612428 Phase 3
33 Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817) Withdrawn NCT01452295 Phase 2, Phase 3 ELAD (Extracorporeal Liver Assist System)
34 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
35 An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis Completed NCT03432260 Phase 2 DUR-928
36 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
37 An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis Completed NCT02655510 Phase 1, Phase 2 F-652
38 A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Completed NCT02019056 Phase 2 Placebo /bid P.O;MG-1;MG-2 : MG1000mg, Placebo /bid P.O;metadoxine
39 A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis Completed NCT01968382 Phase 2 IMM 124-E (Hyperimmune Bovine Colostrum);Placebo (High protein milk powder)
40 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis Completed NCT01903798 Phase 2 Mycophenolate mofetil;Prednisolone;Rilonacept
41 Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study. Completed NCT02265328 Phase 2
42 Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial Completed NCT00851981 Phase 2
43 Long-Term Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00062764 Phase 2 Actos (Pioglitazone)
44 Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00013598 Phase 2 Pioglitazone
45 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Recruiting NCT03829683 Phase 2 Vitamin C;Dextrose 5% in water
46 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis Recruiting NCT02776059 Phase 2 Standard of care + pegfiltrastim;Standard of care
47 IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) Recruiting NCT03775109 Phase 2 Canakinumab 150mg/ml solution for injection;Placebo
48 The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Active, not recruiting NCT03294941 Phase 2
49 A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis. Not yet recruiting NCT03452540 Phase 2 DS102
50 A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium Not yet recruiting NCT04072822 Phase 2 Anakinra and Zinc;Prednisone;Placebos

Search NIH Clinical Center for Alcoholic Hepatitis

Genetic Tests for Alcoholic Hepatitis

Anatomical Context for Alcoholic Hepatitis

MalaCards organs/tissues related to Alcoholic Hepatitis:

40
Liver, Neutrophil, Testes, Brain, Eye, Skin, Monocytes

Publications for Alcoholic Hepatitis

Articles related to Alcoholic Hepatitis:

(show top 50) (show all 2741)
# Title Authors PMID Year
1
Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. 54 61
19094193 2010
2
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 61 54
19769633 2009
3
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. 61 54
19834427 2009
4
[Hepato-biliary and pancreatic disease and osteodystrophy]. 54 61
19721198 2009
5
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 61 54
19663083 2009
6
Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. 54 61
18618253 2009
7
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. 61 54
19033535 2009
8
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. 61 54
19175915 2009
9
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. 54 61
18848937 2008
10
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. 61 54
19038698 2008
11
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. 61 54
18687753 2008
12
Serum TNF-alpha levels in relation to alcohol consumption and common TNF gene polymorphisms. 54 61
18579335 2008
13
Potential role of ADAMTS13 in the progression of alcoholic hepatitis. 61 54
19630717 2008
14
The -308 TNFalpha gene polymorphism in severe acute alcoholic hepatitis: identification of a new susceptibility marker. 54 61
18336639 2008
15
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 61 54
17498256 2007
16
Serum concentrations of interleukin-8 in relation to different levels of alcohol consumption. 54 61
17576072 2007
17
Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. 61 54
17331163 2007
18
Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. 61 54
17331172 2007
19
[Utility of analytical parameters in the diagnosis of liver disease]. 54 61
17373869 2007
20
New treatments of hepatorenal syndrome. 54 61
16850375 2006
21
Combined polymorphisms of tumour necrosis factor alpha and interleukin-10 genes in patients with alcoholic hepatitis. 61 54
16702858 2006
22
Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapheresis. 61 54
16508230 2006
23
Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. 54 61
16762691 2006
24
[Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease]. 61 54
17036498 2006
25
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 61 54
16385229 2005
26
[Genetic susceptibility to the development of acute alcoholic hepatitis: role of genetic mutations in dehydrogenase alcohol, aldehyde dehydrogenase and cytochrome P450 2E1]. 54 61
16324524 2005
27
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. 61 54
16344606 2005
28
Apoptosis in liver diseases--detection and therapeutic applications. 54 61
16258409 2005
29
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease. 54 61
15964033 2005
30
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. 61 54
16009691 2005
31
Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. 61 54
15878216 2005
32
Expression of apolipoprotein AI mRNA in peripheral white blood cells of patients with alcoholic liver disease. 61 54
15949702 2005
33
Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. 61 54
15864177 2005
34
Effects of acetaldehyde and TNF alpha on the inhibitory kappa B-alpha protein and nuclear factor kappa B activation in hepatic stellate cells. 61 54
15550448 2005
35
Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. 54 61
15601573 2004
36
Relation of tumor necrosis factor (TNF) gene polymorphisms with serum concentrations and in vitro production of TNF-alpha and interleukin-8 in heavy drinkers. 54 61
15902922 2004
37
Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. 54 61
15331349 2004
38
Serum levels of tissue polypeptide specific antigen are correlated with hepatocyte cytokeratin expression in alcoholic liver disease. 54 61
15365314 2004
39
Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. 61 54
15288471 2004
40
Effect of prostaglandin E receptor subtype EP4 selective agonist on the secretion of tumor necrosis factor-alpha by macrophages in acute ethanol-loaded rats. 61 54
15318098 2004
41
Diagnosis and therapy of alcoholic liver disease. 54 61
15349802 2004
42
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. 54 61
15122768 2004
43
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. 61 54
15046213 2004
44
New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. 61 54
14720455 2004
45
The effect of alcohol consumption on endothelial adhesion molecule expression. 54 61
14690873 2003
46
Hepatorenal syndrome. 61 54
14654322 2003
47
Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. 61 54
12865279 2003
48
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. 54 61
12663232 2003
49
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? 61 54
12663246 2003
50
[Alcoholic liver disease--established treatment and new therapeutic approaches]. 61 54
12695940 2003

Variations for Alcoholic Hepatitis

Expression for Alcoholic Hepatitis

LifeMap Discovery
Genes differentially expressed in tissues of Alcoholic Hepatitis patients vs. healthy controls: 35 (show top 50) (show all 111)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Liver + 8.79 0.000
2 KRT23 keratin 23, type I Liver + 7.04 0.000
3 FOS FBJ murine osteosarcoma viral oncogene homolog Liver - 6.75 0.000
4 CCL20 chemokine (C-C motif) ligand 20 Liver + 6.56 0.000
5 KCNN2 potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 Liver - 6.11 0.000
6 SPINK1 serine peptidase inhibitor, Kazal type 1 Liver + 6.07 0.000
7 SPP1 secreted phosphoprotein 1 Liver + 6.04 0.000
8 LCN2 lipocalin 2 Liver + 5.74 0.000
9 CXCL6 chemokine (C-X-C motif) ligand 6 Liver + 5.55 0.000
10 COL1A2 collagen, type I, alpha 2 Liver + 5.33 0.000
11 FOSB FBJ murine osteosarcoma viral oncogene homolog B Liver - 5.08 0.000
12 LOXL4 lysyl oxidase-like 4 Liver + 5.01 0.000
13 PDZK1IP1 PDZK1 interacting protein 1 Liver + 4.95 0.000
14 CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 Liver - 4.91 0.000
15 GOLM1 golgi membrane protein 1 Liver + 4.87 0.000
16 NR4A2 nuclear receptor subfamily 4, group A, member 2 Liver - 4.85 0.000
17 MMP7 matrix metallopeptidase 7 Liver + 4.73 0.000
18 EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 Liver + 4.63 0.000
19 CD24 CD24 molecule Liver + 4.57 0.000
20 GNMT glycine N-methyltransferase Liver - 4.50 0.000
21 PCOLCE2 procollagen C-endopeptidase enhancer 2 Liver - 4.48 0.000
22 CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 Liver - 4.45 0.000
23 TACSTD2 tumor-associated calcium signal transducer 2 Liver + 4.41 0.000
24 DCDC2 doublecortin domain containing 2 Liver + 4.28 0.000
25 EPCAM epithelial cell adhesion molecule Liver + 4.26 0.000
26 NQO1 NAD(P)H dehydrogenase, quinone 1 Liver + 4.10 0.000
27 MT1M metallothionein 1M Liver - 4.07 0.000
28 SOX9 SRY (sex determining region Y)-box 9 Liver + 3.99 0.000
29 THBS2 thrombospondin 2 Liver + 3.98 0.000
30 KRT7 keratin 7, type II Liver + 3.96 0.000
31 BICC1 BicC family RNA binding protein 1 Liver + 3.96 0.000
32 FABP4 fatty acid binding protein 4, adipocyte Liver + 3.94 0.000
33 IL32 interleukin 32 Liver + 3.94 0.000
34 PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A Liver - 3.91 0.000
35 RRM2 ribonucleotide reductase M2 Liver + 3.90 0.000
36 CXCL8 chemokine (C-X-C motif) ligand 8 Liver + 3.90 0.000
37 VCAN versican Liver + 3.90 0.000
38 COL1A1 collagen, type I, alpha 1 Liver + 3.89 0.000
39 DUSP1 dual specificity phosphatase 1 Liver - 3.89 0.000
40 LGSN lengsin, lens protein with glutamine synthetase domain Liver - 3.78 0.000
41 COL5A1 collagen, type V, alpha 1 Liver + 3.77 0.000
42 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Liver - 3.77 0.000
43 RGS4 regulator of G-protein signaling 4 Liver + 3.76 0.000
44 STMN2 stathmin 2 Liver + 3.72 0.000
45 SOX4 SRY (sex determining region Y)-box 4 Liver + 3.71 0.000
46 CLEC4M C-type lectin domain family 4, member M Liver - 3.69 0.000
47 ANXA2 annexin A2 Liver + 3.67 0.000
48 ANXA2P2 annexin A2 pseudogene 2 Liver + 3.66 0.000
49 CNDP1 carnosine dipeptidase 1 (metallopeptidase M20 family) Liver - 3.65 0.000
50 GPR88 G protein-coupled receptor 88 Liver - 3.64 0.000
Search GEO for disease gene expression data for Alcoholic Hepatitis.

Pathways for Alcoholic Hepatitis

Pathways related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNF TLR4 IL6 IL1B IL10 HGF
2
Show member pathways
13.59 TNF IL6 IL1B IL10 ICAM1 HGF
3
Show member pathways
13.45 TNF TLR4 IL6 IL1B IL10 HGF
4
Show member pathways
13.43 TNF LBP IL6 IL1B IL10 ICAM1
5
Show member pathways
13.34 TNF IL6 IL1B IL10 HGF CXCL8
6
Show member pathways
13.13 TNF TLR4 LBP IL6 IL1B IL10
7
Show member pathways
13.01 TNF TLR4 IL6 IL1B ICAM1 CXCL8
8
Show member pathways
12.91 TNF IL6 IL1B IL10 ICAM1 CXCL8
9
Show member pathways
12.9 TNF TLR4 IL6 IL1B ICAM1 CXCL8
10
Show member pathways
12.76 TNF TLR4 IL6 IL1B CXCL8
11
Show member pathways
12.74 TNF TLR4 IL6 IL1B HGF
12
Show member pathways
12.67 TNF IL6 IL1B IL10 F2 CCL2
13
Show member pathways
12.65 TNF TLR4 IL6 IL1B IL10
14
Show member pathways
12.64 TNF TLR4 IL6 IL1B IL10
15
Show member pathways
12.42 TNF IL6 IL1B CXCL8 CCL2
16 12.41 TNF TLR4 IL1B CXCL8
17
Show member pathways
12.41 TNF IL6 IL10 CXCL8 CCL2
18
Show member pathways
12.41 TNF TLR4 LBP IL6 IL1B CXCL8
19 12.39 TNF TLR4 IL6 IL1B CXCL8
20 12.37 TNF TLR4 IL6 IL1B F2 CXCL8
21
Show member pathways
12.35 TNF IL6 IL1B IL10 HGF CXCL8
22 12.33 TNF TLR4 IL6 IL1B CXCL8 CCL2
23 12.32 TNF TLR4 LBP IL6 IL1B IL10
24
Show member pathways
12.3 TNF TLR4 IL6 CXCL8
25
Show member pathways
12.3 TNF TLR4 IL1B IL10
26
Show member pathways
12.28 TNF TLR4 LBP IL6 IL1B CXCL8
27 12.27 TNF IL6 IL1B IL10 CXCL8
28
Show member pathways
12.25 TNF IL6 IL1B IL10
29
Show member pathways
12.24 TNF IL6 IL1B ICAM1 GGT1 F2
30 12.14 TNF IL1B ICAM1 CCL2
31 12.08 TNF IL6 IL1B ICAM1 CCL2
32
Show member pathways
12.05 TNF TLR4 IL6 IL1B IL10
33 12.03 TNF TLR4 LBP IL1B ICAM1 CXCL8
34 12.03 TNF TLR4 IL6 IL1B IL10 CXCL8
35 12.01 TNF TLR4 IL6 IL1B IL10 CXCL8
36
Show member pathways
11.99 TLR4 LBP IL6 ICAM1 CXCL8
37 11.99 TNF IL6 IL1B ICAM1 CXCL8 CCL2
38 11.99 TNF TLR4 IL6 IL1B ICAM1 CXCL8
39 11.85 TNF IL6 IL1B IL10
40 11.83 TNF TLR4 IL6 IL1B ICAM1 CXCL8
41 11.81 TNF IL1B IL10
42 11.81 TNF TLR4 IL6 IL1B IL10 CXCL8
43
Show member pathways
11.76 TNF IL6 IL1B ICAM1 CXCL8
44 11.71 TNF TLR4 IL6 IL1B CXCL8
45 11.71 TNF IL6 IL1B HGF CXCL8 CCL2
46 11.67 TNF LBP IL6 IL1B IL10 ICAM1
47 11.63 TNF TLR4 IL1B CCL2
48 11.62 TNF TLR4 LBP
49 11.57 TNF IL6 ICAM1
50 11.54 TNF IL6 IL1B

GO Terms for Alcoholic Hepatitis

Cellular components related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF LBP IL6 IL1B IL10 HGF
2 extracellular space GO:0005615 9.5 TNF LBP IL6 IL1B IL10 ICAM1

Biological processes related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.11 TNF TLR4 IL6 IL1B CRP
2 immune response GO:0006955 10.07 TNF TLR4 IL6 IL1B IL10 CXCL8
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF TLR4 ICAM1 CCL2
4 inflammatory response GO:0006954 10 TNF TLR4 IL6 IL1B CXCL8 CRP
5 leukocyte migration GO:0050900 9.99 TNF IL1B ICAM1 F2
6 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL1B HGF F2
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 TNF TLR4 IL6 IL1B ICAM1
8 cellular response to tumor necrosis factor GO:0071356 9.95 ICAM1 CXCL8 CCL2 ADAMTS13
9 response to bacterium GO:0009617 9.94 TLR4 SLC17A5 CYP2E1 CCL2
10 activation of MAPK activity GO:0000187 9.93 TNF TLR4 IL1B HGF
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 TNF IL6 IL1B IL10
12 defense response to Gram-positive bacterium GO:0050830 9.92 TNF LBP IL6 CRP
13 cellular response to interferon-gamma GO:0071346 9.91 TLR4 ICAM1 CCL2 ADAMTS13
14 neutrophil chemotaxis GO:0030593 9.89 IL1B CXCL8 CCL2
15 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL1B CCL2
16 response to glucocorticoid GO:0051384 9.87 TNF IL6 IL10
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR4 IL1B
18 humoral immune response GO:0006959 9.86 TNF IL6 CCL2
19 negative regulation of tumor necrosis factor production GO:0032720 9.85 TLR4 LBP IL10
20 response to lipopolysaccharide GO:0032496 9.85 TLR4 LBP IL1B IL10 ICAM1 GGT1
21 positive regulation of interferon-gamma production GO:0032729 9.84 TNF TLR4 IL1B
22 positive regulation of interleukin-6 secretion GO:2000778 9.83 TNF TLR4 IL1B
23 protein kinase B signaling GO:0043491 9.82 TNF IL1B CCL2
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 TNF TLR4 IL1B ICAM1
25 acute-phase response GO:0006953 9.8 LBP IL6 F2 CRP
26 negative regulation of neurogenesis GO:0050768 9.79 TNF IL6 IL1B
27 negative regulation of interleukin-6 production GO:0032715 9.78 TNF TLR4 IL10 HGF
28 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TNF TLR4 IL6
29 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
30 positive regulation of macrophage activation GO:0043032 9.76 TLR4 LBP IL10
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
32 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.74 TNF IL6 ICAM1
33 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL6 IL10 F2
34 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6 IL1B
35 cellular response to lipoteichoic acid GO:0071223 9.71 TLR4 LBP
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 TLR4 IL10
37 negative regulation of lipid storage GO:0010888 9.71 TNF IL6 CRP
38 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 LBP IL1B
39 opsonization GO:0008228 9.7 LBP CRP
40 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
41 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
42 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
43 positive regulation of fever generation GO:0031622 9.67 TNF IL1B
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 TNF IL10
45 sequestering of triglyceride GO:0030730 9.65 TNF IL1B
46 positive regulation of interleukin-6 production GO:0032755 9.65 TNF TLR4 LBP IL6 IL1B
47 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 TNF IL1B
48 receptor biosynthetic process GO:0032800 9.63 TNF IL10
49 positive regulation of chemokine production GO:0032722 9.62 TNF TLR4 LBP IL6
50 cytokine-mediated signaling pathway GO:0019221 9.61 TNF LBP IL6 IL1B IL10 ICAM1

Molecular functions related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IL10 HGF F2
2 lipopolysaccharide binding GO:0001530 9.13 TLR4 LBP F2
3 cytokine activity GO:0005125 9.1 TNF IL6 IL1B IL10 CXCL8 CCL2

Sources for Alcoholic Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....